YARW

SEC source: 0001209191-18-005827 · doc4.xml · derivative · entry 7

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Fund VIII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,348,550 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F2 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F2 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F2 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005827 · doc4.xml · nonDerivative · entry 6

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Surplus Fund III, L.P.

Disclosed balance after: 486,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005827 · doc4.xml · nonDerivative · entry 5

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Fund VIII, L.P.

Disclosed balance after: 3,524,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005827 · doc4.xml · nonDerivative · entry 4

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Surplus Fund III, L.P.

Disclosed balance after: 359,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005827 · doc4.xml · nonDerivative · entry 3

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Fund VIII, L.P.

Disclosed balance after: 2,606,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005841 · doc4.xml · derivative · entry 3

venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,196,552 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005841 · doc4.xml · nonDerivative · entry 2

venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,461,552

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005831 · doc4.xml · derivative · entry 7

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 304,576 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005831 · doc4.xml · derivative · entry 6

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 871,583 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005831 · doc4.xml · derivative · entry 5

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 4

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,761,663

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 3

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,457,087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 2

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,585,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.

SEC source: 0000315066-18-000119 · primary_doc.xml · derivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 0

Underlying: Common Stock · 304,576 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

F1 · price: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

F1 · derivative.exercise_date: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

F1 · derivative.expiration_date: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

SEC source: 0000315066-18-000119 · primary_doc.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 0

Underlying: Common Stock · 813,478 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

F1 · price: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

F1 · derivative.exercise_date: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

F1 · derivative.expiration_date: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

SEC source: 0000315066-18-000119 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 1,118,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

SEC source: 0000315066-18-000119 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 813,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock.

SEC source: 0001209191-18-005829 · doc4.xml · nonDerivative · entry 2

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Surplus Fund III, L.P.

Disclosed balance after: 35,686

F1 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F2 · ownership.nature: Albert Cha, a director of the issuer, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005829 · doc4.xml · nonDerivative · entry 1

Vivo Capital VIII, LLC · CIK 0001618789 · 10% owner

Vivo Capital Surplus Fund VIII, L.P. · CIK 0001628048 · 10% owner

Vivo Capital Fund VIII, L.P. · CIK 0001618788 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Fund VIII, L.P.

Disclosed balance after: 258,432

F1 · ownership.nature: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F2 · ownership.nature: Albert Cha, a director of the issuer, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005827 · doc4.xml · nonDerivative · entry 2

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Surplus Fund III, L.P.

Disclosed balance after: 35,686

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005827 · doc4.xml · nonDerivative · entry 1

Cha Albert · CIK 0001397906 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vivo Capital Fund VIII, L.P.

Disclosed balance after: 258,432

F1 · ownership.nature: The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-18-005841 · doc4.xml · nonDerivative · entry 1

venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,000

SEC source: 0001209191-18-005831 · doc4.xml · nonDerivative · entry 1

Remeditex Ventures LLC · CIK 0001627363 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,582,854